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Abstract
 
Biochemical and functional studies have demonstrated major histocompatibility complex
(MHC) class II–restricted presentation of select epitopes derived from cytoplasmic antigens,
with few insights into the processing reactions necessary for this alternate pathway. Efficient
presentation of an immunodominant epitope derived from glutamate decarboxylase (GAD)
was observed regardless of whether this antigen was delivered exogenously or via a cytoplasmic
route into human histocompatibility leukocyte antigen class II–DR4
 
1 
 
antigen-presenting cells.
Presentation of exogenous as well as cytoplasmic GAD required the intersection of GAD pep-
tides and newly synthesized class II proteins. By contrast, proteolytic processing of this antigen
was highly dependent upon the route of antigen delivery. Exogenous GAD followed the classi-
cal pathway for antigen processing, with an absolute requirement for endosomal/lysosomal
acidification as well as cysteine and aspartyl proteases resident within these organelles. Presenta-
tion of endogenous GAD was dependent upon the action of cytoplasmic proteases, including
the proteasome and calpain. Thus, translocation of processed antigen from the cytoplasm into
membrane organelles is necessary for class II–restricted presentation via this alternate pathway.
Further trimming of these peptides after translocation was mediated by acidic proteases within
endosomes/lysosomes, possibly after or before class II antigen binding. These studies suggest
that processing of exogenous and cytoplasmic proteins occurs through divergent but overlap-
ping pathways. Furthermore, two cytoplasmic proteases, the proteasome and calpain, appear to
play important roles in MHC class II–restricted antigen presentation.
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Introduction
 
MHC class II molecules selectively present peptides derived
 
from self- and foreign antigens to CD4
 
1
 
 T cells, providing
a physiological survey of host integrity. Biochemical studies
to define the source of antigenic peptides associated with
class II molecules have revealed a predominance of peptides
derived from exogenous antigens, as well as epitopes from
the plasma membrane and endosomal proteins (1, 2). Such
ligands would predictably intersect class II protein in transit
to the cell surface via the endosomal pathway (3, 4). By
contrast, the observation that peptides derived from cyto-
plasmic antigens are also presented by class II proteins ap-
pears more difficult to reconcile. Epitopes from both solu-
ble and membrane-bound proteins localized within the
cytoplasm have been observed to be efficiently presented
by class II complexes using human and murine APCs (5, 6).
Furthermore, studies suggest that some viral epitopes de-
rived from cytoplasmic antigens gain access to class II pro-
teins for presentation (7, 8). Cytoplasmic antigens have
long been established as the primary source of peptides for
MHC class I molecules, although studies suggest that in
specialized APCs, class I molecules may access proteins
within endosomal/phagosomal compartments (9, 10). Like-
wise, class II proteins may have evolved mechanisms to
sample antigenic peptides within the cytoplasm, potentiat-
ing helper T cell responses to intracellular pathogens and
the maintenance of self-tolerance (6).
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Peptides derived from extracellular or exogenous anti-
gens are generated by processing reactions localized within
a complex network of endosomal and lysosomal vesicles
(11). Antigen denaturation by the acid pH within these or-
ganelles coupled with the action of resident endopeptidases
and carboxypeptidases appears to be a key step in the gen-
eration of ligands for MHC class II complexes. Chief
among these proteases are the cathepsins with acidic pH
optima and a broad range of substrate specificity (12).
These include the cysteine proteases cathepsins B, H, S,
and L and the aspartic hydrolases cathepsins D and E.
Cathepsins have been implicated in the processing of a va-
riety of exogenous antigens for class II–restricted presenta-
tion (13, 14). By contrast, much less is known concerning
the enzymes required for endogenous antigen processing.
Nascent class II proteins are associated with an intracellular
chaperone protein, the invariant chain (Ii),
 
1
 
 which must be
proteolytically processed before peptide binding by these
MHC antigens. Ii serves a dual purpose in protecting the
ligand-binding groove of class II complexes, as well as
guiding class II molecules to endocytic compartments rich
in antigenic peptides. Studies of Ii processing may provide
some insights into the processing environment encoun-
tered by endogenous antigens within endosomes and lyso-
somes, as both cysteine and aspartic cathepsins have been
implicated in Ii degradation (14–16). Studies using mice
genetically targeted to inactivate cathepsin S suggest this
protease functions at a late stage of Ii processing within
professional APCs, whereas cathepsin L appears important
in catalyzing this terminal reaction within thymic cells
(17). Thus, endogenous antigens trafficking through endo-
somes may likely encounter similar proteases to those
functioning in the processing of exogenous proteins. Re-
markably, endogenous cytoplasmic antigens also access the
class II presentation pathway, as shown by class II loading
with epitopes derived from resident cytoplasmic proteins
(18). It remains unclear whether acidic cathepsins or cyto-
plasmic proteases, optimally active at neutral pH, are re-
quired for processing cytoplasmic antigens for MHC class
II–restricted presentation.
This study addresses the requirements for processing and
MHC class II–restricted presentation of the autoantigen
glutamate decarboxylase (GAD) derived exogenously, as
well as from its natural cytoplasmic environment. GAD has
been localized to the cytoplasmic face of membrane or-
ganelles in neuroendocrine cells, and this enzyme repre-
sents a key target autoantigen in several autoimmune disor-
ders, including insulin-dependent diabetes mellitus (IDDM
[19]). Our data demonstrate divergent antigen processing
pathways for exogenous and cytoplasmic GAD. Although
both exogenous and endogenously derived GAD access
endosomal/lysosomal proteases, a distinct cytoplasmic pro-
cessing pathway was identified for GAD originating in the
cytosol. Thus, presentation of cytoplasmic-derived GAD
 
required the function of a cytoplasmic Ca
 
2
 
1
 
-dependent
protease, calpain, and the multicatalytic proteasome. These
results demonstrate that processing reactions within the cy-
toplasm govern the class II–restricted presentation of a sub-
set of endogenous antigens. These studies also revealed that
after translocation from the cytoplasm into membrane or-
ganelles, cytoplasmic antigens are further processed by en-
dosomal/lysosomal proteases before presentation by class II
complexes.
 
Materials and Methods
 
Cell Lines.
 
The B lymphoblastoid cell line (B-LCL) Priess
homozygous for the expression of HLA-DR4 (DRA
 
*
 
0101,
DRB
 
*
 
0401) was maintained in Iscove’s medium (GIBCO BRL)
supplemented with 10% heat-inactivated calf serum. Retroviral
transduction of the parental cell line Priess with the gene encod-
ing the 65-kD form of human GAD resulted in a cell line consti-
tutively expressing this endogenous antigen, termed PriessGAD.
Endogenous GAD expression levels were equivalent using retro-
viral gene transduction or standard transfection methods with
GAD expressed in the pMCFRpacGAD vector (20). Condi-
tioned medium was generated from PriessGAD cells by culturing
overnight, followed by passage of this spent medium through a
0.2-
 
m
 
m filter. The T cell hybridoma 33.1 is specific for the pep-
tide GAD
 
273–285
 
 presented by HLA-DR4 (provided by Linda
Wicker, Merck Research Laboratories, Rahway, NJ). This cell
line was maintained in RPMI (GIBCO BRL) supplemented with
10% FCS, 0.1% 
 
b
 
-mercaptoethanol, and 100 U/ml penicillin and
100 
 
m
 
g/ml streptomycin. Control studies with the class II–nega-
tive cell line, T2, confirmed the DR4 restriction of the 33.1 T
cell. T2 is a B–T cell hybrid with a large deletion of the MHC
class II locus and was maintained in the same tissue culture me-
dium as the Priess cell lines.
 
Inhibitors, Purified Antigen, and Synthetic Peptides. 
 
Chloro-
quine and leupeptin were purchased from Sigma Chemical Co.
and were solubilized in PBS. Cathepsin B inhibitor II, calpeptin,
PD 150606, and lactacystin were purchased from Calbiochem.
These inhibitors, in addition to pepstatin A and brefeldin A (BfA;
Sigma Chemical Co.), were solubilized in DMSO. The recombi-
nant 65-kD form of human GAD was produced in bacteria and
purified to homogeneity using affinity chromatography, as pub-
lished previously (21). Studies indicated that both a truncated
form of recombinant GAD lacking the NH
 
2
 
-terminal domain
and full-length GAD were presented equivalently by APCs.
GAD
 
273–285
 
 (IAFTSEHSHFSLK) was synthesized using an Ap-
plied Biosystems peptide synthesizer and FMOC technology.
Peptide purity and structure was confirmed by reverse phase
HPLC and mass spectroscopy.
 
Electroporation of Antibody into APCs. 
 
PriessGAD cells were
washed twice in ice-cold PBS (GIBCO BRL) and resuspended at
2 
 
3 
 
10
 
7
 
 cells/ml in ice-cold PBS. 50 
 
m
 
l of this cell solution was
placed into 0.4-cm electroporation cuvettes (Bio-Rad) and
placed on ice. 2 
 
m
 
l of mAb raised against calpain I or II (Calbio-
chem), or an IgG1 isotype control (Sigma Chemical Co.) was
added (final antibody concentration of 0.16 
 
m
 
g/ml, 0.4 
 
m
 
g/ml,
and 40 
 
m
 
g/ml, respectively). Each cuvette was gently mixed and
placed on ice for 10 min, then pulsed at 0.270 kV, 0.125 uF (400
ohms resistance). Immediately afterwards, 1 ml of warm media
was added, and the cells were transferred to a 48-well tissue cul-
ture plate. The cells were incubated at 37
 
8
 
C for 20 h and fixed in
1% paraformaldehyde, and GAD was presentation assessed.
 
1
 
Abbreviations used in this paper: 
 
BfA, brefeldin A; B-LCL, B lymphoblas-
toid cell line; GAD, glutamate decarboxylase; IDDM, insulin-dependent
diabetes mellitus; Ii, invariant chain.  
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Subcellular Fractionation and Immunoblotting. 
 
To localize intra-
cellular GAD, cytosolic and membrane organelle fractions were
isolated from PriessGAD as described previously (22). In brief,
cells were lysed using a Balch homogenizer, then differential cen-
trifugation was performed to isolate nuclear, soluble cytoplasmic,
and membrane organelle fractions. Membrane organelles were
washed in a high salt buffer (10 mM Hepes, pH 7.4, 150 mM
NaCl, 10 mM benzamidine, 0.1 mM 
 
p
 
-chloromercuriphenyl sul-
fonic acid [p-CMPS]) to disrupt loosely bound proteins. The iso-
lated particulate and soluble fractions were assayed by Western
blot analysis. For each fraction, equal amounts of protein were
boiled in reducing sample buffer and separated by 12% SDS-
PAGE. The proteins were transferred to a nitrocellulose mem-
brane (Micron Separations, Inc.) and probed with the GAD-spe-
cific mAb GAD6 (23). Bound GAD6 was visualized using goat
anti–mouse horseradish peroxidase (Jackson Laboratories) fol-
lowed by epichemiluminescence (Amersham Pharmacia Biotech).
 
Elution of Peptides from Surface MHC Class II.
 
To remove
acid-labile peptides from cell surface class II complexes, Priess-
GAD cells were washed twice in ice-cold 160 mM NaCl, then
resuspended in 160 mM NaCl/citric acid, pH 4.0 and incubated
for 30 min on ice. These cell preparations were neutralized with
ice-cold medium, then washed twice with fresh tissue culture
medium. No loss in cell viability was observed using these condi-
tions.
 
Antigen Presentation Assays. 
 
For exogenous GAD presenta-
tion studies, Priess cells were preincubated with or without inhib-
itors for 30–60 min. These cells were then incubated with 20 
 
m
 
g/
ml GAD antigen for 18 h at 37
 
8
 
C in the presence or absence of
the inhibitors. Control cells were incubated for 16 h with or
without inhibitors followed by the addition of the GAD
 
273–285
 
peptide for an additional 2 h. Peptide controls were used to en-
sure that inhibitors affect only antigen processing and not class II
maturation or cell surface expression. To monitor endogenous
GAD processing and presentation, PriessGAD cells were incu-
bated with or without inhibitors for 18 h with no visible loss of
viability. For studies with the calpain inhibitor PD150606, APCs
were cultured in Ca
 
2
 
1
 
-free media. B-LCLs typically display a
high Ca
 
2
 
1
 
 influx because of the expression of the EBV-encoded
latent membrane protein 1 (24). In some experiments, Priess-
GAD cells were acid washed before incubation with inhibitors. In
all cases, APCs were subsequently fixed in 1% paraformaldehyde
for 10 min at room temperature and washed extensively in cold
tissue culture medium. After fixation, 2
 
 3 
 
10
 
4
 
 APCs were cocul-
tured with 10
 
4
 
 GAD-specific T hybridoma cells for 24 h at 37
 
8
 
C.
IL-2 production was measured using the IL-2–dependent cell
line, HT-2. HT-2 cells were incubated for 8–16 h with aliquots
of T cell culture supernatants, followed by the addition of
[
 
3
 
H]thymidine. After an additional 8–16 h of incubation at 37
 
8
 
C,
HT-2 cells were harvested using a 96-well plate cell harvester
(Skatron). [
 
3
 
H]thymidine incorporation was measured using a
Wallac microplate reader. The viability of APCs was monitored
in all studies with inhibitors, and the concentrations of drugs were
determined to be nontoxic. The concentrations of proteases in-
hibitors tested did not perturb Ii proteolysis or general class II
protein function, as was demonstrated in control studies monitor-
ing Ii fragmentation and the formation of SDS-stable class II–
peptide complexes using PAGE (13). All T cell assays were per-
formed in triplicate with the mean and SD calculated for each
data point. The percentage of T cell activation of inhibitor-
treated APCs was calculated relative to untreated samples. All fig-
ures are representative of a minimum of three independent ex-
periments.
 
Results
 
GAD Localizes to the Cytoplasmic Face of Membrane Vesicles
in the B-LCL PriessGAD. 
 
In GABA-secreting neurons,
GAD associates with the cytoplasmic face of synaptic vesi-
cles as demonstrated by microscopy and subcellular frac-
tionation (19). Sequences within the NH
 
2
 
-terminal domain
of GAD confer membrane binding such that the bulk of
this protein is found bound to the outer face of vesicular or-
ganelles with only a small amount of soluble cytoplasmic
GAD. Retroviral transduction of the B-LCL Priess with the
human 
 
gad65
 
 gene leads to a similar subcellular distribution
for GAD, with the majority of this protein tightly bound to
the cytosolic face of vesicular membranes (Fig. 1). The lo-
calization of GAD in the transduced B-LCL, PriessGAD,
was accomplished by fractionating cells to separate cytoplas-
mic soluble and membrane-bound proteins, followed by
Western immunoblotting with a GAD-specific mAb. Cy-
toplasmic GAD was predominantly found tightly bound to
membrane organelles, as demonstrated by resistance to high
ionic strength washes designed to disrupt weak membrane–
protein interactions (22). A small but consistent fraction of
GAD molecules partitioned in the cytosol of these APCs.
This distribution mirrors the localization of GAD in neu-
roendocrine cells published previously (22).
 
MHC Class II–restricted Presentation of Cytoplasmic GAD
Occurs through an Endogenous Antigen-processing Pathway
 
.
Several cytoplasmic viral and self-peptides are presented in
the context of MHC class II antigens; however, the specific
pathway for processing and presentation of the epitopes re-
mains unclear (25). Expression of human GAD within the
cytoplasm of the B-LCL PriessGAD resulted in effective
presentation of the immunodominant epitope GAD
 
 273–285
 
,
Figure 1. Endogenously expressed GAD associates with the cytoplas-
mic face of membranes in the B-LCL PriessGAD. Parental Priess (lanes 1,
3, 5, and 7) and PriessGAD (lanes 2, 4, 6, and 8) cells were lysed using an
ice-cold Balch homogenizer. After the removal of nuclei, particulate (M)
and soluble (S1) fractions were separated by centrifugation at 100,000 g.
The membrane pellet was washed to elute loosely associated membrane
proteins, and was centrifuged as before to yield the washed membrane
(WM) fraction and the corresponding supernatant (S2; reference 22). All
fractions were then solubilized in 2% Triton X-100. Equal amounts of to-
tal protein from each fraction were separated by gel electrophoresis and
probed with the mAb GAD6. 
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previously identified using exogenous GAD in DR4
 
1
 
 hu-
man APCs and transgenic mice (20). Immunoblot analysis
failed to detect secreted GAD in conditioned medium from
these cells, suggesting cytoplasmic GAD was processed
through an endogenous mechanism for class II presentation
(data not shown). To confirm that minute quantities of
GAD or GAD-derived peptides were not released by
PriessGAD and presented after endocytosis, functional
studies were conducted to screen for GAD secretion by
these APCs (Fig. 2). Conditioned medium was prepared
from PriessGAD cells, and upon incubation with the pa-
rental DR4
 
1
 
 cell Priess, this medium failed to stimulate
GAD-specific T cells. Incubation of conditioned medium
from PriessGAD cells with viable PriessGAD cells also
failed to significantly enhance or inhibit the inherent pre-
sentation of this endogenous antigen. These results indicate
exogenous GAD or GAD fragments were not released by
transduced cells and could not contribute to the class II–
restricted presentation of this antigen. Thus, efficient presen-
tation of the cytoplasmic self-antigen GAD was not depen-
dent upon secretion and endocytosis of the antigen via the
classical MHC class II processing pathway. Rather, this cy-
toplasmic antigen gains direct access to class II proteins
through an endogenous processing mechanism.
 
Newly Synthesized MHC Class II Molecules Are Required
for Presentation of GAD
 
273–285
 
 Derived from both Exogenous
and Cytoplasmic GAD. 
 
Studies with exogenous antigens
have established that MHC class II proteins access anti-
genic peptides via two distinct pathways (3, 26). Newly
synthesized class II 
 
a
 
/
 
b
 
 heterodimers en route to the cell
surface intersect a wide variety of peptide ligands within
late endosomal- and lysosomal-like compartments such as
MHC class II compartment (11). By contrast, a pool of
mature cell surface class II proteins transit through recy-
cling early endosomal vesicles acquiring distinct antigenic
epitopes via the process of peptide editing. The fungal
product BfA has been widely used to differentiate these
pathways (27, 28). This inhibitor of anterograde move-
ment from the endoplasmic reticulum to the Golgi com-
plex blocks presentation of epitopes by newly synthesized
class II proteins without perturbing the display of peptides
by recycling class II molecules. As expected, this inhibitor
blocked exogenous GAD presentation by HLA-DR4 (Fig.
3 A). Similarly, incubation of PriessGAD cells in the pres-
ence of BfA resulted in a significant reduction in cytoplas-
mic GAD presentation (Fig. 3 B). Presentation of the syn-
thetic GAD peptide was not altered by BfA, as was
expected based on the binding of the peptide to preexist-
ing cell surface class II complexes. Together, these data in-
dicate that presentation of both cytoplasmic and exogenous
GAD was dependent upon the binding of GAD epitopes
to newly synthesized MHC class II 
 
a
 
/
 
b
 
 heterodimers on
route to the cell surface.
Cytoplasmic GAD is constitutively expressed in the
PriessGAD cell line, such that abundant levels of pre-
formed GAD peptide–class II complexes are always present
on the surface of these APCs. Exposing these cells to mild
acid pH or buffers with high ionic strength was found to
release GAD epitopes from class II DR4 molecules on the
cell surface, and permitted analysis of newly formed intra-
cellular peptide–class II complexes in transit to the cell sur-
face (29). These treatments did not alter surface class II
protein peptide binding, nor was the export of newly gen-
erated GAD peptide–class II complexes to the cell surface
perturbed. Disruptions in GAD epitope presentation were
observed in cells using drugs such as BfA regardless of acid
stripping; however, this inhibition was more complete
when the acid stripping protocol was employed.
 
MHC Class II Presents Cytoplasmic GAD Independent of
Endosomal/Lysosomal Acidification.
 
Once resident within
the endocytic pathway, newly synthesized MHC class II
Figure 2. PriessGAD secretes neither GAD nor GAD fragments for re-
uptake via the classical MHC class II pathway. Priess (white bars) or
PriessGAD (gray bars) cells were incubated for 18 h in fresh media or
PriessGAD-conditioned media (CM). These cells were then incubated
with the T cell 33.1 to assess GAD epitope presentation. T cell activation
was not enhanced by incubation of APCs with conditioned media. The
addition of 10 mM GAD273–285 to control APCs resulted in equivalent
stimulation of the T cell 33.1, indicating nearly identical levels of func-
tional HLA-DR4 in both APCs.
Figure 3. Presentation of both exogenous and cytoplasmic forms of
GAD required newly synthesized MHC class II molecules. (A) Priess
cells were preincubated with or without BfA (50 ng/ml), then exoge-
nous GAD was added, and the cells were incubated at 378C for 18 h
(white bars). (B) Acid-stripped PriessGAD cells (gray bars) were incu-
bated for 18 h in the presence or absence of 50 ng/ml BfA. Control sam-
ples were pulsed with 8 mM GAD273–285 (A and B, black bars) 2 h before
fixation. The cells were then paraformaldehyde fixed, and antigen pre-
sentation was assessed using the 33.1 T cell hybridoma as described in
Materials and Methods. Maximal [3H]thymidine incorporation was
14,439 cpm and 32,097 cpm for exogenous and cytoplasmic GAD pre-
sentation, respectively. Maximal cpm for corresponding peptide-pulsed
samples were 416,378 cpm and 340,856 cpm, respectively. Background
(T cells alone) was 3,602 cpm. 
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molecules encounter an acidic environment favoring anti-
gen denaturation and hydrolysis (11). The low pH in late
endosomes and lysosomes may also facilitate conforma-
tional alterations in MHC class II dimers, enhancing in-
teractions with HLA-DM and peptide binding (30).
However, some class II–restricted antigenic epitopes are
presented independent of pH, and there is evidence that
peptides may also be generated in early endosomes with
only mildly acidic pH (3, 31).
To determine whether HLA-DR4–restricted presenta-
tion of GAD
 
 
 
epitopes was dependent upon the acidification
of vesicular organelles, APCs were incubated with the lyso-
somotropic agent chloroquine. This drug has been shown
to block the acidification of late endosomes and lysosomes,
thereby inhibiting endosomal processing by resident cathep-
sins. Presentation of the peptide GAD
 
273–285
 
 derived from
exogenous antigen was completely abrogated at low con-
centrations of chloroquine (Fig. 4 A). However, only min-
imal inhibition in presentation of the same epitope derived
from cytoplasmic GAD was observed, with a significant
portion of this endogenous processing pathway proving re-
sistant to the action of chloroquine (Fig. 4 B). These results
demonstrate that processing and presentation of endoge-
nous GAD, in contrast with exogenous forms of the anti-
gen, does not display absolute dependence upon endo-
some/lysosome acidification. The measurable endogenous
GAD epitope presentation in the presence of chloroquine
further suggests that, at these concentrations, this lysoso-
motropic agent does not abolish intracellular ligand binding
to class II molecules or the transport of class II–peptide
complexes to the cell surface, steps common to both en-
dogenous and exogenous antigen presentation. Studies of
exogenous peptide presentation by class II proteins were
unaltered by chloroquine (Fig. 4), in agreement with control
experiments (data not shown) demonstrating no change in
Ii fragmentation or the formation of stable class II–peptide
complexes using low drug concentrations. Thus, class II
antigen function and surface expression were not grossly
perturbed by the concentrations of chloroquine tested. In
total, these findings suggest that presentation of exogenous
GAD is absolutely dependent upon the acidic environment
found within late endosomes and lysosomes. In contrast,
this critical component of the classical MHC class II pre-
sentation pathway plays a less essential role in processing
GAD originating in the cytoplasm of APCs.
 
Exogenous and Cytoplasmic GAD Are Processed through
Divergent Proteolytic Pathways. 
 
Endocytosed antigens are
cleaved by proteases active within the acidic environment
of endosomal and lysosomal vesicles. By contrast, cytoplas-
mic proteases function to degrade self- and foreign proteins
at neutral pH. To dissect the relative contributions of these
two distinct types of proteases in exogenous and cytoplas-
mic GAD processing and presentation, functional studies
were conducted using class-specific proteolytic inhibitors.
Leupeptin, which inactivates cysteine and serine proteases
including cathepsins B, S, and L, completely blocked the
Figure 4. HLA-DR4–medi-
ated presentation of exogenous
but not cytoplasmic GAD re-
quires acidification of endosomal
and lysosomal vesicles. (A) Priess
cells pulsed with exogenous
GAD were incubated in the
presence or absence of increas-
ing concentrations of chloro-
quine for 18 h (s). (B) Priess-
GAD cells (h) were incubated
with increasing concentrations
of chloroquine. Control APCs
(A [d] and B [j]) were pulsed
with 10 mM GAD273–285 3 h be-
fore fixation in 1% paraformal-
dehyde. Antigen presentation
was assessed as described in Ma-
terials and Methods.
Figure 5. Class II–restricted presentation of exogenous and cytoplasmic
GAD displays differential requirements for endosomal cysteine proteases.
(A) Priess cells pretreated with leupeptin were incubated with exogenous
GAD (s). (B) PriessGAD (h) were treated with increasing concentra-
tions of leupeptin. After exposure to leupeptin, control APCs were pulsed
with 10 mM GAD273–285 (A [d] and B [j]) 3 h before fixation and subse-
quent assessment of GAD presentation, as described in Materials and
Methods. Additionally, Priess cells (C) were exposed to the cathepsin B
inhibitor (CBI II; 10 mM), followed by the addition of exogenous GAD
(white bars). (D) Acid-stripped PriessGAD cells (gray bars) were treated
with the cathepsin B inhibitor (CBI II; 10 mM). Control APCs (C and D,
black bars) with or without cathepsin B inhibitor treatment were pulsed
with 8 mM GAD273–285 2 h before fixation in 1% paraformaldehyde.
GAD-specific presentation was assessed as described in Materials and
Methods. Maximal [3H]thymidine incorporation for untreated samples
was 56,184.7 cpm and 28,241.2 cpm for exogenous and cytoplasmic
GAD presentation, respectively. Maximal [3H]thymidine incorporation
for corresponding peptide-pulsed samples was 65,503.3 cpm and 58,802.9
cpm, respectively. Background (T cells alone) was 1,563.7 cpm. 
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presentation of exogenous GAD (Fig. 5 A). This result is
consistent with the transport of GAD through endosomal
or lysosomal compartments for presentation by class II anti-
gens. By contrast, endogenous GAD processing was only
partially reduced upon incubation of PriessGAD cells with
this peptidyl aldehyde (Fig. 5 B). The concentrations of leu-
peptin tested did not perturb overall class II antigen matu-
ration or surface expression, as demonstrated using syn-
thetic peptides (Fig. 5) and experiments to monitor the
formation of SDS-stable 
 
a
 
/
 
b
 
 dimers and Ii proteolysis (data
not shown).
To further define the role of acidic cysteine proteases in
cytoplasmic antigen processing, GAD presentation was ex-
amined in cells treated with cathepsin B inhibitor II, a leu-
peptin analogue that has been shown to preferentially block
the action of cathepsin B (32). A partial reduction in both
exogenous and cytoplasmic GAD presentation was ob-
served with inhibition of this protease as measured by anti-
gen-specific T cell activation (Fig. 5, C and D). Cathepsin
B has amino- and carboxypeptidase specificity, and within
endosomes this enzyme may serve in the final stages of
trimming GAD epitopes before or after binding to class II
complexes. This is supported by the observation that cathep-
sin B has an occluding loop within its active center, favor-
ing exopeptidase activity while limiting its endopeptidase
activity (33). Overall, these results demonstrate that cyto-
plasmic GAD or fragments of this antigen gain access to en-
dosomal/lysosomal proteases necessary to promote efficient
interactions with class II complexes and T cell recognition.
Equally important, the observation of leupeptin-insensitive
GAD presentation suggests that alternate processing steps
are required for this cytoplasmic antigen.
Pepstatin A is a peptide inhibitor that blocks the activity
of endosomal and lysosomal aspartyl proteases and degrada-
tion of endocytosed antigens in macrophages and B cells
(14). To define a role for these endosomal hydrolases in the
processing of exogenous and cytoplasmic GAD, APCs
were incubated with pepstatin A. This inhibitor of cathep-
sins D and E efficiently blocked presentation of GAD
 
273–285
 
derived from the exogenous form of this antigen (Fig. 6).
By contrast, presentation of cytoplasmic-derived GAD
 
 
 
was
not affected by exposure of cells to pepstatin A. Control
studies confirmed that the expression and function of sur-
face class II proteins were not altered by pepstatin A treat-
ment of cells. These data clearly suggest that MHC class II
presentation of GAD epitopes derived from both exoge-
nous and cytoplasmic antigens follows divergent but over-
lapping processing pathways.
 
Extra-lysosomal Processing Mechanisms Are Involved in
MHC Class II-restricted Presentation of Cytoplasmic GAD.
 
Cytoplasmic proteases function in supplying peptides for
class I–restricted presentation. However, the role of these
enzymes in generating epitopes for class II molecules re-
mains unclear. The proteasome, a large multicatalytic com-
plex found in the nucleus and cytoplasm, is well established
as playing a critical role in class I–mediated immune re-
sponses (34). To examine the role of the proteasome in cy-
toplasmic antigen presentation via MHC class II molecules,
B cells were treated with lactacystin. This proteasome-spe-
cific inhibitor has been shown to block MHC class I pre-
sentation of cytoplasmic antigens (35). As expected, lac-
tacystin treatment of APCs did not inhibit MHC class
II–restricted presentation of exogenous GAD (Fig. 7 A). In
fact, a small but reproducible enhancement of exogenous
GAD presentation via lactacystin treatment of cells was ob-
served, suggesting that downmodulation of the proteasome
may also indirectly enhance antigen processing via the en-
dosomal/lysosomal pathway. Yet when the GAD express-
ing APC, PriessGAD, was incubated with this proteasome
inhibitor, a marked reduction in GAD epitope presentation
Figure 6. Aspartyl protease activity is required for exogenous but not
cytoplasmic GAD processing. Priess cells exposed to variable concentra-
tions of pepstatin A were then incubated for 18 h with exogenous GAD
(s). PriessGAD cells (h) were treated with increasing concentrations of
pepstatin A for an identical time. Control APCs (d and j) with or with-
out pepstatin A treatment were pulsed with 10 mM GAD273–285 3 h before
fixation in 1% paraformaldehyde. GAD-specific antigen presentation was
assessed as described in Materials and Methods.
Figure 7. Proteasome inhibition selectively blocks endogenous GAD
processing and MHC class II–restricted presentation. (A) Priess cells were
preincubated with or without 250 nM lactacystin, a specific inhibitor of
the proteasome, followed by 18-h exposure to exogenous GAD (white
bars). (B) Acid-washed PriessGAD cells (gray bars) were incubated for 18 h
with or without the proteasome-specific inhibitor lactacystin (250 nM).
Control APCs (A and B, black bars) were pulsed with 8 mM GAD273–285 2 h
before fixation in 1% paraformaldehyde. Antigen presentation was as-
sessed as described in Materials and Methods. [3H]thymidine incorpora-
tion for untreated samples was 62,397.6 cpm and 27,784.1 cpm for exog-
enous and cytoplasmic GAD presentation, respectively. [3H]thymidine
incorporation for corresponding peptide pulsed samples was 81,696.3
cpm and 95,691.4 cpm, respectively. Background (T cells alone) was
1,059 cpm. 
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was detected (Fig. 7 B). Given the reported specificity of
lactacystin for the proteasome, these results clearly provide
evidence that blocking proteasome activity can influence
the MHC class II presentation pathway. These studies were
conducted using concentrations of lactacystin demonstrated
not to perturb cell viability or trigger apoptosis, even after
24 h of treatment (data not shown). Lactacystin has been
used to inactivate the proteasome in APCs, and blocks the
generation of endogenous peptides required for assembly
and stable surface expression of MHC class I (36). Surface
class I antigen expression was reduced at least 30% in cells
exposed to low concentration of this drug overnight, con-
firming proteasome inactivation (data not shown).
Complete inhibition of endogenous GAD presentation
in lactacystin treated cells was not obtained, suggesting
multiple enzymes may function in processing this cytoplas-
mic antigen for the class II pathway. Moreover, studies us-
ing lactacystin have established that certain class I epitopes
are not dependent upon proteasome activity, thus alluding
to the presence of additional cytoplasmic proteases in-
volved in presentation of endogenous antigens (36, 37). In
the cytoplasm, calcium-dependent cysteine proteases have
been shown to modulate signal transduction pathways and
transcription mechanisms through their endoproteolytic
processing function (38). Calpains are found in the cyto-
plasm bound to intracellular membranes, as well as parti-
tioning in the soluble fraction, prompting us to examine
the role of this protease in processing endogenous GAD
(39). Calpeptin is a membrane permeable inhibitor with a
demonstrated specificity for cytoplasmic calpains (40, 41).
As expected, treatment of APCs with low concentrations
of calpeptin did not significantly alter class II presentation
of exogenously derived GAD
 
 
 
(Fig. 8 A). In contrast, incu-
bation of PriessGAD with calpeptin completely inhibited the
presentation of cytoplasmic-derived GAD (Fig. 8 B). Stud-
ies with control APCs pulsed with synthetic GAD
 
273–285
 
indicated that exposing cells to calpeptin did not effect
overall class II antigen expression and function, nor was the
formation of peptide–class II complex formation perturbed,
as assessed by SDS-stable dimer stability assays and analysis
of Ii proteolysis (data not shown). At higher concentrations
of calpeptin (.10 mM), inhibition of exogenous GAD pre-
sentation could be detected. However, this was accompa-
nied by a concomitant decrease in presentation of synthetic
peptide, suggesting perturbation in overall class II matura-
tion. Indeed, at high dosages of calpeptin, Ii cleavage frag-
ments indicative of disturbances in endosomal protease
function were detected (data not shown). Nonetheless, at
the calpeptin concentrations used in this functional study,
only the presentation of cytoplasmic-derived GAD was sig-
nificantly altered in APCs (Fig. 8).
To further explore the novel prospect that calpains were
involved in MHC class II–restricted presentation of cyto-
plasmic GAD, we employed the nonpeptidyl inhibitor
PD150606. This mercaptoacrylic acid derivative has been
shown to selectively block calpain activity by reversibly
binding to the Ca21-binding domain of the protease (42).
Thus, unlike peptidyl inhibitors, there is no requirement
for competitive binding within the active site of the hydro-
lase, preventing any cross-reactivity of this inhibitor with
calcium-independent proteases such as cathepsins B, L, and
S. Treatment of APCs with PD150606 caused a marked re-
duction in cytoplasmic GAD presentation (Fig. 8 C).
An alternate technique to specifically interrupt the activ-
ity of intracellular enzymes is through the use of mAbs. Lu-
kas et al. (43) have shown that mAbs specific for cyclin D1
introduced into viable cells through electroporation can ar-
rest cell cycle progression. Two calpain isozymes have been
identified in B cells: calpain I (requiring micromolar Ca21)
and calpain II (requiring millimolar Ca21; reference 44).
Remarkably, introduction of an mAb specific for calpain I
into electrically permeabilized PriessGAD cells reduced cy-
toplasmic GAD presentation (Fig. 9). An antibody specific
for calpain II displayed significantly less ability to inhibit
GAD presentation. Parallel control studies with an irrele-
vant isotype control mAb failed to produce significant inhi-
bition of class II restricted presentation of this cytoplasmic
antigen.
Taken together, these results demonstrate a key role for
calcium-dependent calpains in the processing pathway of
cytoplasmic antigens for presentation by MHC class II mol-
ecules. Epitopes derived from both soluble and membrane-
Figure 8. Inhibition of the neutral cytoplasmic protease calpain de-
creases presentation of cytoplasmic GAD. (A) Priess cells were pretreated
with 5 mM calpeptin, then incubated for 18 h in the presence of exoge-
nous GAD (white bars). (B) Acid-washed PriessGAD cells (gray bars)
were treated with or without the calpain-selective inhibitor calpeptin (5
mM). These samples were run in parallel to those described in Fig. 7, and
percentage T cell activation was calculated relative to untreated samples
shown in Fig. 7. (C) Acid-washed PriessGAD cells (gray bars) were resus-
pended in Ca21-free DMEM/10% heat-inactivated calf serum and incu-
bated in the presence of the calpain-selective inhibitor PD150606 for 20 h.
Maximal [3H]thymidine incorporation was 158,388 cpm for untreated
APCs and 192,482 cpm for the corresponding peptide control. In both
experiments (A–C), control APCs (black bars) were treated plus or minus
inhibitor and incubated for an identical period, then pulsed with 8 mM
GAD273–285 2 h before fixation. GAD-specific presentation was assessed as
described in Materials and Methods.1520 Cytoplasmic Processing of Antigens for Class II–restricted Presentation
bound cytoplasmic proteins gain access to class II molecules
(8, 25). Calpain exhibits a parallel distribution, thereby po-
tentiating its contact with both classes of cytoplasmic anti-
gens and possibly favoring the transport of nascent peptides
across membranes into organelles containing receptive class
II molecules.
Discussion
Optimal activation of humoral and cell-mediated immu-
nity in response to intracellular viral and bacterial pathogens
is dependent upon stimulation of CD41 T cells via class II–
restricted antigen presentation. Studies with MHC class II–
deficient mice and type II bare lymphocyte patients indicate
a clear role for class II proteins in contributing to immunity
against these pathogens (45, 46). Biochemical studies have
revealed epitopes derived from endogenous cytoplasmic an-
tigens bound to MHC class II proteins, suggesting that se-
lect intracellular antigens gain access to class II proteins.
Further, in vivo studies have also demonstrated a role for
cytoplasmic antigens in inducing central tolerance via class
II–restricted presentation in the thymus. To begin to un-
ravel the mechanisms underlying these critical immunologic
functions, an in vitro model system was designed to directly
compare the antigen processing mechanisms of exogenous
and cytoplasmic forms of GAD.
Presentation of cytoplasmic antigens by class II proteins
may occur through several potential mechanisms. During
infection of APCs, pathogens may enter endosomes or phago-
somes before delivery into the cytoplasm, leading to pro-
cessing of pathogen-derived proteins by compartmentalized
acidic proteases, and presentation by class II proteins within
these organelles (47). Alternatively, APCs may endocytose
pathogenic antigens released during lysis of infected host
cells through the process of bystander presentation (48). Fi-
nally, as demonstrated in this study, cytoplasmic antigens
may be processed by proteases within the cytoplasm of the
APCs, then translocated into membrane organelles contain-
ing MHC class II proteins. Evidence that peptides derived
from a cytoplasmic antigen, GAD, gain direct access to
newly synthesized class II proteins was obtained in EBV-
transformed B-LCLs. Presentation of endogenous GAD
epitopes was only marginally dependent upon key features
of the classical pathway for exogenous antigen processing
and display, including acidification of endosomal/lysosomal
compartments and activation of cysteine proteases resident
within these organelles. Rather, an absolute requirement
for cytoplasmic antigen processing was observed for presen-
tation of endogenous GAD epitopes. Thus, proteases re-
sponsible for generating peptide ligands for MHC class I
molecules appear to also function in supplying epitopes for
presentation by class II complexes. Evidence was obtained
suggesting that both the proteasome and a calcium-acti-
vated protease calpain participate in processing antigens for
class II–restricted presentation. These studies suggest a
sequential mechanism whereby cytoplasmic antigens are
cleaved by neutral proteases before translocation into or-
ganelles containing class II molecules. The final stages of an-
tigen processing or trimming of these epitopes may be me-
diated within endosomes by proteases such as cathepsin B,
before or after binding to class II complexes.
The antigen selected for this study, GAD, has been iden-
tified as a key target in several autoimmune disorders in-
volving the neuroendocrine system (19). In insulin-depen-
dent diabetes, autoantibodies to GAD are among the
earliest hallmarks of progression to disease, with measurable
T cell responses to this antigen noted in both humans and
mice (19). In addition, a strong genetic link between sus-
ceptibility to IDDM and specific MHC class II alleles has
been found in both humans and rodents (49), with B cells
playing an essential role in progression to disease (50). The
development of diabetes can be ablated in NOD mice im-
munized with tolerogenic levels of GAD (51). Thus, studies
to examine the processing of exogenous GAD may have
relevance to both the induction and prevention of this au-
toimmune disorder. Presentation of an immunodominant
epitope derived from exogenous GAD by APCs was de-
pendent upon acidification of endosomes and lysosomes,
suggesting that processing or binding of this epitope occurs
in these acidic organelles. Consistent with this result, pro-
cessing of exogenous GAD by both cysteine and aspartyl
proteases was a prerequisite to efficient class II–restricted
presentation of this autoantigen via B cells. Disruptions in
autoantigen processing can block the development of
autoimmune disease, as was recently demonstrated with
cathepsin S knockout mice and collagen-induced arthritis
(52). Although cysteine proteases such as cathepsin S play a
role in processing a variety of antigens (53, 54), the role of
aspartyl proteases in antigen presentation appears more re-
stricted (12, 14, 15). Thus, inactivation of the aspartyl pro-
tease required for exogenous GAD processing may hold
promise as a preventative treatment for IDDM.
Unexpectedly, endogenous GAD molecules produced
within the cytoplasm of cells also gain access to the class II
Figure 9. Introduction of calpain-specific antibodies into PriessGAD
cells suppresses cytoplasmic GAD presentation. PriessGAD cells were
electrically permeabilized in the presence or absence of anti–calpain I
(CANP I), anti–calpain II (CANP II), or an isotype control antibody. Af-
ter electroporation, the cells were incubated for 20 h and fixed in 1%
paraformaldehyde, and GAD presentation was assessed.1521 Lich et al.
pathway for presentation (20). The processing of endoge-
nous GAD was clearly distinct from the exogenous antigen,
as determined by susceptibility to protease inhibitors. Thus,
aspartyl proteases are not required for endogenous GAD
presentation. Further, inhibitors of acidic cysteine proteases
only partially block GAD epitope formation, suggesting
that these enzymes may play a role in the final stages of
epitope trimming. By contrast, at least two distinct cyto-
plasmic proteases, the proteasome and calpain, function in
processing endogenous GAD for class II–restricted presen-
tation.
A role for the multicatalytic proteasome in processing
cytoplasmic GAD for class II–restricted presentation was dem-
onstrated in this study using the specific inhibitor lactacys-
tin. The proteasome rapidly catalyzes the turnover of short-
lived and abnormally folded proteins within the cytoplasm
(34). Yet, prior studies have shown that both long- and
short-lived cytoplasmic antigens are presented by class II
molecules (55). Ubiquination and processing by the protea-
some also favors proteins with basic NH2-terminal residues
as defined by the N-end rule pathway (56). However, gen-
eration of cytosolic antigens with basic NH2-terminal resi-
dues did not always favor class II–mediated presentation,
and proteasome cleavage of substrates via the N-end rule
appears to vary with cell type (8). These findings, along
with the demonstration that acidification of endosomal/
lysosomal compartments was sometimes important for pre-
sentation of many cytoplasmic antigens via class II mole-
cules (7, 55), raised questions as to the requirement for the
proteasome in the class II pathway. The requirement for
endosomal/lysosomal acidification is not at odds with a role
for the proteasome, as proteases in these organelles may play
a role in the final trimming of peptides for class II presenta-
tion. Alternatively, the acid pH within these organelles may
favor peptide binding to class II molecules (30). As the pro-
teasome can generate peptides of variable length (57), it is
reasonable to hypothesize that this complex may supply
ligands not only for MHC class I–restricted but also for class
II–restricted presentation.
Previous studies designed to implicate the proteasome in
antigen processing for class I have alluded to the potential
role of other cytoplasmic proteases. In fact, it has been
shown that nonproteasomal hydrolytic activity within the
cytoplasm can influence class I–restricted presentation (37,
58). Lymphoid and myeloid cells express at least two
calpain isozymes, calpain I and calpain II, with the activa-
tion of these enzymes linked to cytoplasmic calcium levels
(44). In this study, MHC class II–restricted presentation of
an endogenous cytoplasmic antigen was ablated after inhibi-
tion of the calcium-dependent protease calpain with the
peptidyl inhibitor calpeptin. Additionally, presentation of
cytoplasmic GAD was diminished in the presence of
PD150606, an inhibitor of calcium-dependent calpains as
well as mAbs to calpains. Remarkably, both calpain and
GAD share a similar subcellular distribution within the cy-
toplasm, existing in both membrane and soluble forms.
GAD has been localized to the cytoplasmic face of granules
within neuroendocrine cells (19, 22), whereas calpains have
been observed to bind to the cytoplasmic face of the plasma
membrane, coated vesicles, and the endoplasmic reticulum
(39). Whether the membrane localization of GAD and
calpain play a role in favoring the translocation of GAD
epitopes into organelles rich in class II proteins is currently
under investigation. In contrast with cathepsins and the
proteasome, calpains exhibit greater substrate selectivity and
have been implicated in cleavage of IkBa, the common g
chain receptor, and ZAP70 in immune cells (59, 60). Thus,
engineering antigens for calpain cleavage and membrane
translocation may hold potential as a novel methodology for
vaccine delivery to the class II pathway. Calpains have been
linked with several pathological conditions, including the
autoimmune disorders arthritis, multiple sclerosis, and ex-
perimental allergic encephalomyelitis (44, 61). The impor-
tance of calpains in processing antigens for class I presen-
tation remains unclear. Interestingly, however, several
peptidyl aldehydes used to inactivate the proteasome and
demonstrated to block class I presentation were originally
isolated as calpain inhibitors.
MHC class II molecules bind and present peptides de-
rived from antigens originating within the cytoplasm of the
APC. Unfortunately, the mechanisms underlying this non-
classical mode of antigen presentation remain largely un-
known. This study demonstrates for the first time that cy-
toplasmic resident proteases are involved in MHC class II
presentation of endogenous antigens. The requirement for
cytoplasmic antigen processing provides a key insight into
this alternate pathway for antigen presentation. However,
the method of translocation of cytoplasmic antigen into
class II–containing vesicles remains a mystery. Delivery of
intact cytoplasmic antigens into class II–rich compartments
by autophagy had been speculated to be one means of facil-
itating the intersection of antigenic epitopes and class II
molecules. Yet, the current study demonstrates a clear re-
quirement for processing before antigen delivery into
membrane organelles. Thus, a specific mechanism for pep-
tide translocation and delivery to class II proteins appears to
be necessary. Whether the transport of these epitopes is
linked to transporter associated with antigen processing (7,
62), an endosomal/lysosomal heat shock cognate protein
(63), or an alternate translocation machinery requires fur-
ther investigation.
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